Geographic Atrophy: Clinical Trials

78 completed, 32 recruiting, 24 terminated, 15 active not recruiting. 68 Phase 2, 37 Phase 1, 29 Not applicable, 22 Phase 3, 7 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	68	Completed 27, Recruiting 15, Terminated 13, Active not recruiting 5, Unknown 3, Withdrawn 3, Enrolling by invitation 1, Not yet recruiting 1
Phase 1	37	Completed 19, Recruiting 11, Active not recruiting 2, Terminated 2, Unknown 2, Withdrawn 1
Not applicable	29	Completed 8, Recruiting 6, Unknown 4, Active not recruiting 3, Withdrawn 3, Enrolling by invitation 2, Not yet recruiting 2, Terminated 1
Phase 3	22	Completed 12, Terminated 4, Active not recruiting 2, Recruiting 2, Not yet recruiting 1, Withdrawn 1
Phase 4	7	Completed 6, Active not recruiting 1
Early Phase 1	1	Not yet recruiting 1

Follow Geographic Atrophy: new trials by email Literature Review of Geographic Atrophy trials Research Report on Geographic Atrophy

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) Vonaprument - Geographic Atrophy	Phase 3	Not yet recruiting	Annexon, Inc.	605	2026-09-30	2026-09-08
Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study Adaptive Optics Scanning Light Ophthalmoscopy, Microperimetry, Optical Coherence Tomography - Geographic Atrophy	Not applicable	Enrolling by invitation	University of Wisconsin, Madison	10	2026-09-29	2026-09-01
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration BRX011, Placebo - Geographic Atrophy	Phase 1 / Phase 2	Recruiting	Biojiva LLC	152	2026-09-29	2026-09-23
A Study in Adults With Geographic Atrophy STL303, Placebo - Geographic Atrophy	Phase 2	Recruiting	Sitala Bio LTD	300	2026-09-11	2026-09-21
An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy PST-611 - Geographic Atrophy, Age - Related Macular Degeneration (AMD)	Phase 2	Not yet recruiting	Eyevensys	24	2026-09-01	2026-07-16
Safety and Efficacy Study of Novel Gene Therapy AGX-08 for Geographic Atrophy AGX-08-L, AGX-08-H, AGX-08-S - Geographic Atrophy	Early Phase 1	Not yet recruiting	Zhongmou Therapeutics	24	2026-07-01	2026-07-31
A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy TO-O-1007 (low-dose), TO-O-1007 (high-dose), Sham injection - Geographic Atrophy Due to Age-Related Macular Degeneration	Phase 1 / Phase 2	Recruiting	Theratocular Biotek Co.	31	2026-06-02	2026-06-25
Pterygopalatine Ganglion Stimulation for the Treatment of Geographic Atrophy Pterygopalatine ganglion stimulation, Sham pterygopalatine ganglion stimulation - Geographic Atrophy	Not applicable	Not yet recruiting	Shanghai Institute of Acupuncture, Moxibustion and Meridian	62	2026-06-01	2026-05-06
Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy Transcorneal electrical stimulation (TES) with the OkuStim 2 System - Geographic Atrophy Secondary to Age-related Macular Degeneration	Not applicable	Recruiting	Okuvision GmbH	70	2026-05-05	2026-07-28
Phase 1 Study of C.001 in Retinal Degeneration Injection - Geographic Atrophy, Stargardt Disease	Phase 1	Recruiting	Cellio Therapeutics Inc	15	2026-04-07	2026-08-17
Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints Object recognition and selection task - Dry AMD, Geographic Atrophy	Not applicable	Not yet recruiting	Streetlab	60	2026-04-01	2026-02-25
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants Pozelimab - Geographic Atrophy (GA)	Phase 1	Recruiting	Regeneron Pharmaceuticals	54	2026-01-19	2026-08-05
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD BS01, Sham procedure control - Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)	Phase 1 / Phase 2	Recruiting	Bionic Sight LLC	40	2026-01-08	2026-01-23
Wide Field OCTA in Ocular Diseases Age - Related Macular Degeneration (AMD), Diabetic Macular Edema		Not yet recruiting	IRCCS San Raffaele	200	2026-01-01	2025-12-30
SGLT2 Inhibitors in Geographic Atrophy Dapagliflozin, Matching Placebo - Retinal Degeneration, Retinal Diseases	Phase 2	Recruiting	Washington University School of Medicine	70	2025-12-02	2026-08-26
Ocular Proteomics Testing In Chronic Atrophy AC Tap (anterior chamber paracenthesis) - Age-Related (Dry) Macular Degeneration	Not applicable	Active not recruiting	ClinOmicsAI	50	2025-11-30	2026-05-01
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham - Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)	Phase 2	Recruiting	ONL Therapeutics	324	2025-10-28	2026-09-10
Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe APL-2, Pegcetacoplan - Geographic Atrophy Secondary to Age-related Macular Degeneration	Phase 3	Completed	Apellis Pharmaceuticals, Inc.	44	2025-10-24	2025-12-17
Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD hiPSC-RPEs - AMD - Age-Related Macular Degeneration	Phase 1 / Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	12	2025-10-14	2026-10-19
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration SAR446597, Sham Comparator - Geographic Atrophy	Phase 1 / Phase 2	Recruiting	Sanofi	104	2025-10-09	2026-10-20

Showing 20 of 178. Sign in to see all of them.

Narrower conditions

Macular Degeneration (116)  ·  Retinal Diseases (17)  ·  Wet Macular Degeneration (15)  ·  Eye Diseases (14)  ·  Retinal Degeneration (14)  ·  Vision Disorders (12)  ·  Choroidal Neovascularization (11)  ·  Anetoderma (6)  ·  Retinal Vein Occlusion (6)  ·  Stargardt Disease (5)  ·  Diabetic Retinopathy (4)  ·  Macular Edema (4)  ·  Retinitis Pigmentosa (4)  ·  Blindness (3)

Broader conditions

Eye Diseases (164)  ·  Retinal Degeneration (164)  ·  Retinal Diseases (161)  ·  Macular Degeneration (62)  ·  Pathological Conditions, Signs and Symptoms (24)  ·  Eye Diseases, Hereditary (19)  ·  Nervous System Diseases (16)  ·  Neurologic Manifestations (14)  ·  Sensation Disorders (14)  ·  Signs and Symptoms (14)  ·  Uveal Diseases (13)  ·  Choroid Diseases (12)  ·  Pathologic Processes (12)  ·  Metaplasia (11)  ·  Neovascularization, Pathologic (11)

Interventions

salicylhydroxamic acid (13)  ·  pegcetacoplan (7)  ·  Ranibizumab (6)  ·  brolucizumab (5)  ·  lampalizumab (5)  ·  Sirolimus (3)  ·  emixustat (3)  ·  Tacrolimus (2)  ·  Tomography, Optical Coherence (2)  ·  aflibercept (2)  ·  Acyclovir (1)  ·  Bevacizumab (1)  ·  Brimonidine Tartrate (1)  ·  Contraceptives, Oral (1)  ·  Doxycycline (1)

Sponsors

Novartis Pharmaceuticals (14)  ·  Genentech, Inc. (8)  ·  Apellis Pharmaceuticals, Inc. (7)  ·  Hoffmann-La Roche (7)  ·  Alcon Research (5)  ·  Gyroscope Therapeutics Limited (5)  ·  Janssen Research & Development, LLC (5)  ·  National Eye Institute (NEI) (5)  ·  Boehringer Ingelheim (4)  ·  Annexon, Inc. (3)  ·  Astellas Institute for Regenerative Medicine (3)  ·  Institut de la Macula y la Retina (3)  ·  Kubota Vision Inc. (3)  ·  Science Corporation (3)  ·  University Hospital, Bonn (3)

Countries

United States (122)  ·  Australia (38)  ·  Germany (37)  ·  United Kingdom (34)  ·  Spain (29)  ·  France (28)  ·  Italy (25)  ·  Canada (18)  ·  Poland (18)  ·  Czechia (15)  ·  Austria (14)  ·  Hungary (14)  ·  Netherlands (13)  ·  Switzerland (13)  ·  Israel (11)

Top investigators

Amitha Domalpally, MD, PhD (2)  ·  Erich Strauss, M.D. (2)  ·  Jeffrey Weiss, MD (2)  ·  Nadia Waheed, MD (2)  ·  Philip Rosenfield, MD, PhD (2)  ·  Steven Levy, MD (2)

Results publications

PMID 37314061, PMID 39758130, PMID 33331670, PMID 39102242, PMID 20688734, PMID 22281388, PMID 25458728, PMID 26199618, PMID 26604914, PMID 27857759, PMID 27904503, PMID 28475704, PMID 29110945, PMID 29558533, PMID 29781974, PMID 29801123, PMID 32199866, PMID 33383315, PMID 37428131, PMID 37702300, PMID 37865470, PMID 37869030, PMID 38722644, PMID 38814626, PMID 38900484, PMID 40280279, PMID 40388106, PMID 42668567, PMID 11297486, PMID 11933894, PMID 12003606, PMID 12967792, PMID 15557456, PMID 15813972, PMID 15864618, PMID 15965170, PMID 16123434, PMID 16283987, PMID 16723482, PMID 17188044, PMID 17675159, PMID 1850220, PMID 1922252, PMID 19365036, PMID 19592101, PMID 19797219, PMID 20110127, PMID 20357194, PMID 20574018, PMID 20926818

NIH funding

2014 (5), 2019 (4), 2025 (3), 2015 (1), 2016 (1), 2018 (1), 2023 (1), R01EY009859 (1), R01EY034965 (1), R24EY019861 (1), R44EY018990 (1)